Life science investment group Abingworth Management has launched a specialist fund aimed at high net...
Life science investment group Abingworth Management has launched a specialist fund aimed at high net worth investors, which will invest in under-appreciated life science stocks. The Abingworth BioEquities Fund (ABE), which will be managed Joe Anderson, will invest broadly across the life sciences field including human therapeutics and healthcare. As well as investing in small and mid-cap stocks in the open market, ABE will also invest in public companies through PIPEs and negotiated transactions. Anderson, who is a partner in Abingworth as well as portfolio manager, said: "Many developme...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes